T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026
2026/04
15
Join our presentation at the BIOLOGICS WORLD TAIWAN 2026
2026/03
18
Our Latest Research Published in International Journal of Pharmaceutics
2026/03
16
TE-6168 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
2026/03
03
T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones
2026/01
29